These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 27543821

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, King M, Kihira S, Babb J, Thung S, Taouli B.
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF.
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
    [Abstract] [Full Text] [Related]

  • 6. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M.
    World J Gastroenterol; 2017 May 28; 23(20):3690-3701. PubMed ID: 28611522
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
    Liu L, Wang W, Chen H, Zhao Y, Bai W, Yin Z, He C, Jia J, Yang M, Xia J, Fan D, Han G.
    Clin Cancer Res; 2014 Mar 15; 20(6):1623-31. PubMed ID: 24493832
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N, Osuga K, Higashihara H, Tomoda K, Mikami K, Nakazawa T, Nakamura H, Tomiyama N.
    Cardiovasc Intervent Radiol; 2012 Feb 15; 35(1):82-9. PubMed ID: 21203761
    [Abstract] [Full Text] [Related]

  • 14. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.
    Kim MN, Kim BK, Han KH, Kim SU.
    Expert Rev Gastroenterol Hepatol; 2015 Mar 15; 9(3):335-48. PubMed ID: 25370168
    [Abstract] [Full Text] [Related]

  • 15. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation.
    Zhang W, Xu AH, Wang W, Wu YH, Sun QL, Shu C.
    BMC Cancer; 2019 Nov 05; 19(1):1041. PubMed ID: 31690274
    [Abstract] [Full Text] [Related]

  • 16. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.
    Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim MJ.
    Liver Int; 2014 Feb 05; 34(2):305-12. PubMed ID: 23890360
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
    Miki I, Murata S, Uchiyama F, Yasui D, Ueda T, Sugihara F, Saito H, Yamaguchi H, Murakami R, Kawamoto C, Uchida E, Kumita SI.
    World J Gastroenterol; 2017 Sep 21; 23(35):6437-6447. PubMed ID: 29085193
    [Abstract] [Full Text] [Related]

  • 18. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, Kim HS.
    Ann Oncol; 2013 Apr 21; 24(4):965-73. PubMed ID: 23223331
    [Abstract] [Full Text] [Related]

  • 19. Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response.
    Hu J, Maybody M, Cao G, Wang X, Chen H, Zhu X, Yang R, Wang X.
    Cancer Imaging; 2016 Oct 03; 16(1):32. PubMed ID: 27716376
    [Abstract] [Full Text] [Related]

  • 20. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.
    Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ.
    Radiology; 2012 Feb 03; 262(2):708-18. PubMed ID: 22187634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.